Skip to main content
SpringerLink
Log in

Cytokine Response Modifiers

  • Chapter
Principles of Molecular Rheumatology

Part of the book series: Current Molecular Medicine ((CMM,volume 1))

  • 91 Accesses

Abstract

The development of cytokine-based therapies (supplementation or antagonism) for treatment of connective tissue diseases such as rheumatoid arthritis (RA) has been an area of intense investigation for over 10 yr. This interest stems from four general observations: (1) Cytokine secretion (along with cell—cell cognate interaction) is a method of regulation and information exchange among the cellular constituents of the immune system (1), (2) abnormal immunologic regulation forms the milieu in which such diseases become manifest; (3) the relative lack of efficacy, along with significant toxicity, displayed by currently available therapies (2), and (4) developments in molecular biology that have advanced the questions that may be asked from a basic research standpoint as well as potential clinical interventions arising from those investigations (3).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lotz, M. (1997). Cytokines and their receptors, in Arthritis and Allied Conditions: A Textbook of Rheumatology, 13th ed. (Koopman, W. J., ed.), Williams & Wilkins, Baltimore, pp. 439–478.

    Google Scholar 

  2. Jain, R. and Lipsky, P. E. (1997) Treatment of rheumatoid arthritis. Med Clin. North Am. 81, 57–84.

    Article  PubMed  CAS  Google Scholar 

  3. Moreland, L. M. and Koopman, W. J. (1997) Biologic agents as potential therapies for autoimmune diseases, in Arthritis and Allied Conditions: A Textbook of Rheumatology, 13th ed. (Koopman, W. J., ed.), Williams & Wilkins, Baltimore pp. 777–809.

    Google Scholar 

  4. Moreland, L. W., Heck, L. W., and Koopman, W. J. (1997) Biologic agents for treating rheumatoid arthritis: concepts and progress. Arthritis Rheum. 40, 397–409.

    Article  PubMed  CAS  Google Scholar 

  5. Moreland, L. M., Morgan, E. E., Adamson, T. C, et al. (1998) T Cell receptor peptide vaccination in rheumatoid arthritis: a placebo controlled trial using a combination of Vb3, Vβ14, and Vβ17 peptides. Arthritis Rheum. 41, 1919–1929.

    Article  PubMed  CAS  Google Scholar 

  6. Webb, G. R., Westacott, C. I., and Elson, C. J. (1998) Osteoarthritic synovial fluid and synovium supernatants upregulate tumor necrosis factor receptors on human articular chondrocytes. Osteoarthritis Cart. 6, 167–176.

    Article  CAS  Google Scholar 

  7. Joosten, L. A. B., Helsen, M. M. A., van de Loo, F. A. J., and van den Berg, W. B. (1996) Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL- l alpha.beta and IL-1 RA. Arthritis Rheum. 39, 797–809.

    Article  PubMed  CAS  Google Scholar 

  8. van de Loo, F. A., Joosten, L. A., van Lent, P. L., et al. (1995) Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum. 38, 164–172.

    Article  PubMed  Google Scholar 

  9. Eliaz, R., Wallach, D., and Korst, J. (1995) Long-term protection against the effects of tumor necrosis factor by controlled delivery of the soluble p55 TNF receptor. Cytokine 9, 482–487.

    Google Scholar 

  10. Campion, G. V., Lebsack, M. E., Lookabaugh, J., et al. (1996) Dose-range and frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum. 39, 1092–1101.

    Article  PubMed  CAS  Google Scholar 

  11. Bresnihan, B. (on behalf of the collaborating investigators), Lookbaugh, J., Witt, K., and Musikic, P. (1996) Treatment with recombinant human interleukin- 1 receptor antagonist (rhulL-1 RA) in rheumatoid arthritis (RA): results of a randomized double-blind, placebo controlled multicenter trial. Arthritis Rheum. 39, S73 (abstract).

    Article  Google Scholar 

  12. Felson, D. T., Anderson, J. J., Boers, M., et al. (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 36, 729–740.

    Article  PubMed  CAS  Google Scholar 

  13. Brennan, F. M., Maini, R. N., and Feldmann, M. (1992) TNF alpha—a pivotal role in rheumatoid arthritis? Br. J. Rheum. 31, 293–298.

    Article  CAS  Google Scholar 

  14. Gatanaga, T., Hwang, C. D., Kohr, W., et al. (1990) Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc. Natl. Acad. Sci. USA 87, 8781–8784.

    Article  PubMed  CAS  Google Scholar 

  15. Maini, R. N., Breedveld, F. C., Kalden, J. R., et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552–1563.

    Article  PubMed  CAS  Google Scholar 

  16. Main, R., St. Clair, E. W., Breedveld, F., et al. (1999) Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354, 1932–1939.

    Article  Google Scholar 

  17. Paleolog, E. M., Young, S., Stark, A. C., McCloskey, R. V., Feldmann, M., and Maini, R. N. (1998) Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 41, 1258–1265.

    Article  PubMed  CAS  Google Scholar 

  18. Moreland, L. M. (1998) Soluble tumor necrosis factor receptor (p75) fusion protein (EnbrelTM) as a therapy for rheumatoid arthritis. Rheum. Dis. Clin. North Am. 24, 579–591.

    Article  PubMed  CAS  Google Scholar 

  19. Moreland, L. W., Margolies, G. R., Heck, L. W., et al. (1996) Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol. 23, 1849–1855.

    PubMed  CAS  Google Scholar 

  20. Moreland, L. W., Baumgartner, S. W., Schiff, M. H., et al. (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor(p75)—Fc fusion protein. N. Engl. J. Med. 337, 141–147.

    Article  PubMed  CAS  Google Scholar 

  21. Moreland, L. W., Schiff, M. H., Baumgartner, S. W., et al. (1999) Recombinant human tumor necrosis factor receptor (p75) : Fc fusion protein in rheumatoid arthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Ann. Int. Med. 130, 478–486.

    PubMed  CAS  Google Scholar 

  22. Moreland, L. W., Baumgartner, S. W., Tindall, E., et al. (1998) Long term treatment of rheumatoid arthritis with the receptor p75 Fc fusion protein (TNFR : Fc; EnbrelTM). Arthritis Rheum. 41(Suppl.), S364.

    Google Scholar 

  23. Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., et al. (1998) A controlled trial of etanercept, a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340, 253–257.

    Article  Google Scholar 

  24. Lovell, D. J., Giannini, E. H., Reiff, A., et al. (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N. Engl. J. Med. 342, 763–769.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Richard E. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Larry W. Moreland
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Walter Reed Army Institute of Research, Silver Spring, MD, USA

    George C. Tsokos MD

  2. Uniformed Services University of the Health Sciences, Bethesda, MD, USA

    George C. Tsokos MD

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Jones, R.E., Moreland, L.W. (2000). Cytokine Response Modifiers. In: Tsokos, G.C. (eds) Principles of Molecular Rheumatology. Current Molecular Medicine, vol 1. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-018-6_31

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-018-6_31

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-182-0

  • Online ISBN: 978-1-59259-018-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation